Department of Systems Medicine, University of Rome Tor Vergata, 00173 Rome, Italy.
Laboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.
Nutrients. 2018 Nov 14;10(11):1756. doi: 10.3390/nu10111756.
Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis, all processes that are crucial for tumour infiltrative behaviour and the metastatic process. In addition, EA may increase tumour sensitivity to chemotherapy and radiotherapy. The aim of this review is to summarize the in vitro and in vivo experimental evidence supporting the anticancer activity of pure EA, its metabolites, and EA-containing fruit juice or extracts in a variety of solid tumour models. The EA oral administration as supportive therapy to standard chemotherapy has been recently evaluated in small clinical studies with colorectal or prostate cancer patients. Novel formulations with improved solubility and bioavailability are expected to fully develop the therapeutic potential of EA derivatives in the near future.
鞣花酸（EA）是一种天然存在的多酚化合物，具有很强的抗氧化和抗癌特性，在各种浆果、石榴和干果中含量很高。EA 的抗肿瘤活性主要归因于直接的增殖抑制和凋亡作用。此外，EA 可以抑制肿瘤细胞迁移、细胞外基质侵袭和血管生成，所有这些过程对于肿瘤浸润行为和转移过程都至关重要。此外，EA 可能会增加肿瘤对化疗和放疗的敏感性。本综述的目的是总结支持纯 EA、其代谢物以及含有 EA 的果汁或提取物在各种实体瘤模型中的抗癌活性的体外和体内实验证据。EA 作为标准化疗的辅助治疗已在结直肠癌或前列腺癌患者的小型临床研究中进行了评估。具有改善的溶解度和生物利用度的新型制剂有望在不久的将来充分发挥 EA 衍生物的治疗潜力。
